Ancora Advisors’s Capricor Therapeutics CAPR Stock Holding History

Ancora Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,786	Closed	-$64K	–	2249
2022 Q1	$64K	Buy	+1,786	New	+$7.04K	﹤0.01%	1150

Other funds holding CAPR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ancora Advisors's CAPR Position: Q2 2022 in Review

Ancora Advisors sold out of Capricor Therapeutics (CAPR) in Q2 2022, closing a stake of 1,786 shares — an estimated $64K sold.

Ancora Advisors first reported a position in CAPR in Q1 2022 and held it in 1 quarter. The position peaked at $64K in Q1 2022. 29 funds tracked by Wall St. Rank hold CAPR as of Q2 2022.

Ancora Advisors reported no remaining Capricor Therapeutics position as of Q2 2022 after selling out during the quarter.
Ancora Advisors sold 1,786 Capricor Therapeutics shares in Q2 2022, an estimated $64K.
Ancora Advisors first reported a position in Capricor Therapeutics in Q1 2022 and held it in 1 quarter.
Ancora Advisors's Capricor Therapeutics position peaked at $64K in Q1 2022.
29 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2022.

Based on Ancora Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.